Objective-To assess the effects on haemodynamic function and symptoms of percutaneous balloon dilatation of mitral stenosis in patients unable to undergo surgical treatment because of associated medical/cardiac problems.
Design-A review of clinical outcome in 28 patients (of 108 undergoing balloon dilatation of the mitral valve) who were unsuitable for surgery.
Setting-A tertiary cardiac referral centre: some patients referred were from other cardiac centres in Scotland.
Patients-28 patients judged by cardiac surgeons to be unsuitable for valve replacement or valvotomy because of respiratory disease (15 patients), nonmitral cardiac disease (6) , multi-organ impairment (5), psychiatric problems (1) or dense intrathoracic adhesions (1) .
Interventions-Percutaneous anterograde balloon dilatation of the mitral valve with polyethylene/polyvinyl balloons in 20 patients and the Inoue balloon in eight patients. Main outcome measures--Haemodynamic variables were measured before and immediately after mitral valve dilatation. Patient survival and symptom class (New York Heart Association) were followed for a year after the procedure.
Results-Dilatation at the mitral orifice was achieved in all cases. The mean (SD) pressure drop across the valve fell from 13-9 (5 3) to 5 6 (2 5) mm Hg, cardiac output rose from [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] (1) (2) to (2) (3) (4) (5) I/min, and valve area increased from 0-78 (0-32) to cm2. The and cerebral vascular disease, left ventricular one (patient 28), who had previously underimpairment, and coronary artery disease. gone mitral valvotomy, had dense intraGroup B-Severe non-mitral cardiac dis-thoracic adhesions that caused an attempt ease: six patients were in this category. Three at valve replacement to be abandoned. had severe left ventricular impairment (ejecThe mean (SD) age of the 28 patients was tion fractions 10, 15, and 25% and the last two 66-7 (7-4) years (range 53-78). There were 21 had additional coronary disease) and three had women and seven men. A history of rheumatic severe diffuse coronary artery disease unsuit-fever was reported by eight (29%) and seven able for coronary artery bypass grafts.
(25%) had had a valvotomy, including two Group C-Multiorgan impairment: five patients had two previous surgical valvopatients had severe multi-system medical tomies. The mean daily dose of frusemide at problems (table 2) . the time of dilatation was 144 mg (range 40-Group D-Miscellaneous: one (patient 27) 500 mg). These 28 patients had been referred had severe depression and schizophrenia and from cardiac departments throughout the five patients with multi-organ medical problems showed some early symptomatic improvement and one had died.
Two patients have had a repeat balloon dilatation procedure for re-stenosis (one five months and one 21 months after the first.)
Twenty one patients were reviewed one year after balloon dilatation and seven were reviewed at 8-12 months (fig 2 and table 1 ). In the group with respiratory disease two further patients had died: nine (60%) continued to show some symptomatic improvement up to one year after dilatation. Of the six patients with additional severe cardiac disease, two patients had died by one year, two showed continued improvement, and one patient had reverted to NYHA symptom class IV. In the group of five patients with severe general medical problems three had died by one year, one again had breathlessness at rest, and one showed sustained improvement.
Discussion
The patients in this series were all severely disabled by their breathlessness. All had at least one major associated medical problem that put them at an unacceptably high risk as judged by their cardiac surgeon. In these circumstances balloon dilatation of the mitral valve might be considered successful if it produced a small but significant improvement in exercise capacity or prevented clinical deterioration.
In 
